Ferroptosis Is a Potential Therapeutic Target for Pulmonary Infectious Diseases

Figure 5

Ferroptosis and pulmonary infection caused by SARS-CoV-2. SARS-CoV-2 inhibits the expression of GPX4 and then promotes ferroptosis. GPX4 reduces LPO in biofilms, so upregulation of GPX4 activity reduces inflammatory factors and promotes inflammation regression. A ferroptosis inducer, ACSL1, inhibits syncytial formation and viral transmission in primary macrophages, while reducing lung inflammation and injury in the mouse model of coronavirus infection. SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; GPX4: glutathione peroxidase 4.